Roedl Kevin, Jarczak Dominik, Boenisch Olaf, de Heer Geraldine, Burdelski Christoph, Frings Daniel, Sensen Barbara, Nierhaus Axel, Kluge Stefan, Wichmann Dominic
Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
J Clin Med. 2022 Feb 17;11(4):1049. doi: 10.3390/jcm11041049.
The spread of SARS-CoV-2 caused a worldwide healthcare threat. High critical care admission rates related to Coronavirus Disease 2019 (COVID-19) respiratory failure were observed. Medical advances helped increase the number of patients surviving the acute critical illness. However, some patients require prolonged critical care. Data on the outcome of patients with a chronic critical illness (CCI) are scarce. Single-center retrospective study including all adult critically ill patients with confirmed COVID-19 treated at the Department of Intensive Care Medicine at the University Medical Center Hamburg-Eppendorf, Germany, between 1 March 2020 and 8 August 2021. We identified 304 critically ill patients with COVID-19 during the study period. Of those, 55% ( = 167) had an ICU stay ≥21 days and were defined as chronic critical illness, and 45% ( = 137) had an ICU stay <21 days. Age, sex and BMI were distributed equally between both groups. Patients with CCI had a higher median SAPS II (CCI: 39.5 vs. no-CCI: 38 points, = 0.140) and SOFA score (10 vs. 6, < 0.001) on admission. Seventy-three per cent ( = 223) of patients required invasive mechanical ventilation (MV) (86% vs. 58%; < 0.001). The median duration of MV was 30 (17-49) days and 7 (4-12) days in patients with and without CCI, respectively ( < 0.001). The regression analysis identified ARDS (OR 3.238, 95% CI 1.827-5.740, < 0.001) and referral from another ICU (OR 2.097, 95% CI 1.203-3.654, = 0.009) as factors significantly associated with new-onset of CCI. Overall, we observed an ICU mortality of 38% ( = 115) in the study cohort. In patients with CCI we observed an ICU mortality of 28% ( = 46) compared to 50% ( = 69) in patients without CCI ( < 0.001). The 90-day mortality was 28% ( = 46) compared to 50% ( = 70), respectively ( < 0.001). More than half of critically ill patients with COVID-19 suffer from CCI. Short and long-term survival rates in patients with CCI were high compared to patients without CCI, and prolonged therapy should not be withheld when resources permit prolonged therapy.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的传播对全球医疗保健构成了威胁。观察到与2019冠状病毒病(COVID-19)呼吸衰竭相关的重症监护病房(ICU)高收治率。医学进步有助于增加急性重症疾病存活患者的数量。然而,一些患者需要长期的重症监护。关于慢性重症疾病(CCI)患者结局的数据很少。这是一项单中心回顾性研究,纳入了2020年3月1日至2021年8月8日期间在德国汉堡-埃彭多夫大学医学中心重症医学科接受治疗的所有确诊COVID-19的成年重症患者。在研究期间,我们确定了304例COVID-19重症患者。其中,55%(n = 167)的患者ICU住院时间≥21天,被定义为慢性重症疾病,45%(n = 137)的患者ICU住院时间<21天。两组患者的年龄、性别和体重指数分布相同。CCI患者入院时的简化急性生理学评分系统II(SAPS II)中位数较高(CCI组:39.5分 vs. 非CCI组:38分,P = 0.140),序贯器官衰竭评估(SOFA)评分也较高(10分 vs. 6分,P < 0.001)。73%(n = 223)的患者需要有创机械通气(MV)(86% vs. 58%;P < 0.001)。有CCI和无CCI患者的MV中位持续时间分别为30(17 - 49)天和7(4 - 12)天(P < 0.001)。回归分析确定急性呼吸窘迫综合征(ARDS)(比值比[OR] 3.238,95%置信区间[CI] 1.827 - 5.740,P < 0.001)和从另一个ICU转诊(OR 2.097,95% CI 1.203 - 3.654,P = 0.009)是与新发生CCI显著相关的因素。总体而言,我们观察到研究队列的ICU死亡率为38%(n = 115)。CCI患者的ICU死亡率为28%(n = 46),而无CCI患者为50%(n = 69)(P < 0.001)。90天死亡率分别为28%(n = 46)和50%(n = 70)(P < 0.001)。超过一半的COVID-19重症患者患有CCI。与无CCI患者相比,CCI患者的短期和长期生存率较高,在资源允许进行延长治疗时,不应放弃延长治疗。